journal
https://read.qxmd.com/read/37212969/idh-wild-type-lower-grade-gliomas-with-glioblastoma-molecular-features-a-systematic-review-and-meta-analysis
#21
REVIEW
Satoshi Nakasu, Shoichi Deguchi, Yoko Nakasu
The WHO 2021 classification defines IDH wild type (IDHw) histologically lower-grade glioma (hLGG) as molecular glioblastoma (mGBM) if TERT promoter mutation (pTERTm), EGFR amplification or chromosome seven gain and ten loss aberrations are indicated. We systematically reviewed articles of IDHw hLGGs studies (49 studies, N = 3748) and meta-analyzed mGBM prevalence and overall survival (OS) according to the PRISMA statement. mGBM rates in IDHw hLGG were significantly lower in Asian regions (43.7%, 95% confidence interval [CI: 35...
July 2023: Brain Tumor Pathology
https://read.qxmd.com/read/37273000/%C3%AE-sma-positive-vascular-mural-cells-suppress-cyst-formation-in-hemangioblastoma
#22
JOURNAL ARTICLE
Maki Sakaguchi, Riho Nakajima, Toshiya Ichinose, Shingo Tanaka, Ryouken Kimura, Hemragul Sabit, Satoko Nakada, Mitsutoshi Nakada
Approximately 60% of hemangioblastomas (HBs) have peritumoral cysts adjacent to the tumor, which can cause neurological deficits due to the mass effect, and the management of cyst formation is a clinical challenge. Vascular mural cells surrounding endothelial cells consist of vascular smooth muscle cells (vSMCs) and pericytes, which are essential elements that support blood vessels and regulate permeability. This study investigated the involvement of mural cells in cyst formation. We analyzed the expression of α-smooth muscle actin (α-SMA), platelet-derived growth factor receptor-beta (PDGFRB), and CD31 in 39 consecutive human cerebellar HBs, 20 of cystic and 19 of solid type...
June 5, 2023: Brain Tumor Pathology
https://read.qxmd.com/read/37086325/lynch-syndrome-associated-chordoma-with-high-tumor-mutational-burden-and-significant-response-to-immune-checkpoint-inhibitors
#23
JOURNAL ARTICLE
Naoki Shinojima, Kazutaka Ozono, Haruaki Yamamoto, Sakiko Abe, Rumi Sasaki, Yusuke Tomita, Azusa Kai, Ryosuke Mori, Takahiro Yamamoto, Ken Uekawa, Hirotaka Matsui, Kisato Nosaka, Hiroaki Matsuzaki, Yoshihiro Komohara, Yoshiki Mikami, Akitake Mukasa
Chordoma is a rare malignant bone tumor arising from notochordal tissue. Conventional treatments, such as radical resection and high-dose irradiation, frequently fail to control the tumor, resulting in recurrence and re-growth. In this study, genetic analysis of the tumor in a 72-year-old male patient with refractory conventional chordoma of the skull base revealed a high tumor mutational burden (TMB) and mutations in the MSH6 and MLH1 genes, which are found in Lynch syndrome. The patient and his family had a dense cancer history, and subsequent germline genetic testing revealed Lynch syndrome...
April 22, 2023: Brain Tumor Pathology
https://read.qxmd.com/read/37072666/immunohistochemical-and-ultrastructural-review-of-six-cases-previously-diagnosed-as-null-cell-pitnets
#24
JOURNAL ARTICLE
Naoko Inoshita, Toyoki Yoshimoto, Yutaka Takazawa, Noriaki Fukuhara, Mitsuo Okada, Hiroshi Nishioka, Shozo Yamada
Pituitary neuroendocrine tumors (PitNETs) lacking lineage affiliation are termed "null cell" PitNETs (NCTs). NCTs are characterized as being immunonegative for pituitary hormones as well as transcription factors. We analyzed the ultrastructure and immunohistochemistry of six hormone-negative and transcription factor (TPIT, PIT1, SF1)-negative PitNETs, with less than 1% immunoreactive cells. Histologically, three cases presented a perivascular pattern and pseudorosettes; the other three showed a solid pattern with oncocytic changes...
April 18, 2023: Brain Tumor Pathology
https://read.qxmd.com/read/37041322/spatial-metabolic-heterogeneity-of-oligodendrogliomas-at-single-cell-resolution
#25
JOURNAL ARTICLE
Sai Batchu, Michael Joseph Diaz, Giona Kleinberg, Brandon Lucke-Wold
Oligodendrogliomas are a type of rare and incurable gliomas whose metabolic profiles have yet to be fully examined. The present study examined the spatial differences in metabolic landscapes underlying oligodendrogliomas and should provide unique insights into the metabolic characteristics of these uncommon tumors. Single-cell RNA-sequencing expression profiles from 4044 oligodendroglioma cells derived from tumors resected from four locations frontal, temporal, parietal, and frontotemporoinsular) and in which 1p/19q co-deletion and IDH1 or IDH2 mutations were confirmed were computationally analyzed through a robust workflow to elucidate relative differences in metabolic pathway activities among the different locations...
April 11, 2023: Brain Tumor Pathology
https://read.qxmd.com/read/37022648/an-enduring-debate-on-gliomatosis-cerebri
#26
REVIEW
Jiro Akimoto
Gliomatosis cerebri (GC) is a unique glial tumor that extensively invades the cerebral white matter and has been recognized as an entity of neuroepithelial tumors since the first edition of the WHO classification of brain tumors in 1979. Thereafter, in the fourth edition of the WHO classification in 2007, it was clearly defined as a specific type of astrocytic tumor. However, in the WHO 2016 classification, which was based on the concept of integrated diagnosis using molecular genetics, GC was deleted as it was considered to be only one growth pattern of diffuse glioma and not a specific pathological entity...
April 2023: Brain Tumor Pathology
https://read.qxmd.com/read/37004583/utility-of-genome-wide-dna-methylation-profiling-for-pediatric-type-diffuse-gliomas
#27
REVIEW
Yoshihiro Otani, Kaishi Satomi, Yasuki Suruga, Joji Ishida, Kentaro Fujii, Koichi Ichimura, Isao Date
Despite the current progress of treatment, pediatric-type diffuse glioma is one of the most lethal primary malignant tumors in the central nervous system (CNS). Since pediatric-type CNS tumors are rare disease entities and highly heterogeneous, the diagnosis is challenging. An accurate diagnosis is essential for the choice of optimal treatment, which leads to precision oncology and improvement of the patient's outcome. Genome-wide DNA methylation profiling recently emerged as one of the most important tools for the diagnosis of CNS tumors, and the utility of this novel assay has been reported in both pediatric and adult patients...
April 1, 2023: Brain Tumor Pathology
https://read.qxmd.com/read/36800124/liquid-biomarkers-in-glioma
#28
REVIEW
Sho Tamai, Toshiya Ichinose, Mitsutoshi Nakada
An ideal biomarker must meet several parameters to enable its successful adoption; however, the nature of glioma makes it challenging to discover valuable biomarkers. While biomarkers require simplicity for clinical implementation, anatomical features and the complexity of the brain make it challenging to perform histological examination. Therefore, compared to biomarkers from general histological examination, liquid biomarkers for brain disease offer many more advantages in these minimally invasive methods...
April 2023: Brain Tumor Pathology
https://read.qxmd.com/read/36788155/utility-of-real-time-polymerase-chain-reaction-for-the-assessment-of-cdkn2a-homozygous-deletion-in-adult-type-idh-mutant-astrocytoma
#29
JOURNAL ARTICLE
Yuzaburo Shimizu, Mario Suzuki, Osamu Akiyama, Ikuko Ogino, Yuko Matsushita, Kaishi Satomi, Shunsuke Yanagisawa, Makoto Ohno, Masamichi Takahashi, Yasuji Miyakita, Yoshitaka Narita, Koichi Ichimura, Akihide Kondo
The World Health Organization Classification of Tumors of the Central Nervous System 5th Edition (WHO CNS5) introduced a newly defined astrocytoma, IDH-mutant grade 4, for adult diffuse glioma classification. One of the diagnostic criteria is the presence of a CDKN2A/B homozygous deletion (HD). Here, we report a robust and cost-effective quantitative polymerase chain reaction (qPCR)-based test for assessing CDKN2A HD. A TaqMan copy number assay was performed using a probe located within CDKN2A. The linear correlation between the Ct values and relative CDKN2A copy number was confirmed using a serial mixture of DNA from normal blood and U87MG cells...
April 2023: Brain Tumor Pathology
https://read.qxmd.com/read/36656502/correction-morphologically-genetically-and-spatially-mixed-astrocytoma-and-oligodendroglioma-chronological-acquisition-of-1p-19q-codeletion-and-cdkn2a-deletion-a-case-report
#30
Hirokazu Takami, Akitake Mukasa, Shunsaku Takayanagi, Tsukasa Koike, Reiko Matsuura, Masako Ikemura, Tetsuo Ushiku, Gakushi Yoshikawa, Junji Shibahara, Shota Tanaka, Nobuhito Saito
No abstract text is available yet for this article.
April 2023: Brain Tumor Pathology
https://read.qxmd.com/read/37000254/preface-for-brain-tumor-pathology-vol-40-issue-2-special-issue-for-the-40th-annual-meeting-of-the-japan-society-of-brain-tumor-pathology
#31
EDITORIAL
Atsushi Sasaki
No abstract text is available yet for this article.
March 31, 2023: Brain Tumor Pathology
https://read.qxmd.com/read/36995447/impact-of-tumor-markers-on-diagnosis-treatment-and-prognosis-in-cns-germ-cell-tumors-correlations-with-clinical-practice-and-histopathology
#32
JOURNAL ARTICLE
Hirokazu Takami, Christopher S Graffeo, Avital Perry, Caterina Giannini, Yoichi Nakazato, Nobuhito Saito, Masao Matsutani, Ryo Nishikawa, David J Daniels, Koichi Ichimura
Tumor markers in CNS germ cell tumors (GCTs) include human chorionic gonadotropin (HCG) and alpha fetoprotein (AFP), which have significant diagnostic implications, as elevation of either one leads to clinical diagnosis of non-germinomatous GCTs without histopathological confirmation, justifying intensified chemotherapy and irradiation. The current study, based on an international cohort of histopathologically verified GCTs that underwent biopsy (n = 85) or resection (n = 76), sought to better define the clinical role and prognostic significance of tumor markers from serum and CSF in this challenging patient population...
March 30, 2023: Brain Tumor Pathology
https://read.qxmd.com/read/36991274/easy-to-use-machine-learning-system-for-the-prediction-of-idh-mutation-and-1p-19q-codeletion-using-mri-images-of-adult-type-diffuse-gliomas
#33
JOURNAL ARTICLE
Tomohide Nishikawa, Fumiharu Ohka, Kosuke Aoki, Hiromichi Suzuki, Kazuya Motomura, Junya Yamaguchi, Sachi Maeda, Yuji Kibe, Hiroki Shimizu, Atsushi Natsume, Hideki Innan, Ryuta Saito
Adult-type diffuse gliomas are divided into Astrocytoma, IDH-mutant, Oligodendroglioma, IDH-mutant and 1p/19q-codeleted and Glioblastoma, IDH-wildtype based on the IDH mutation, and 1p/19q codeletion status. To determine the treatment strategy for these tumors, pre-operative prediction of IDH mutation and 1p/19q codeletion status might be effective. Computer-aided diagnosis (CADx) systems using machine learning have been noted as innovative diagnostic methods. However, it is difficult to promote the clinical application of machine learning systems at each institute because the support of various specialists is essential...
March 29, 2023: Brain Tumor Pathology
https://read.qxmd.com/read/36988764/clinical-characteristics-and-radiological-features-of-glioblastoma-idh-wildtype-grade-4-with-histologically-lower-grade-gliomas
#34
REVIEW
Kazuya Motomura, Yuji Kibe, Fumiharu Ohka, Kosuke Aoki, Junya Yamaguchi, Ryuta Saito
The 2021 World Health Organization (WHO) classification of central nervous system tumors applied molecular criteria and further integrated histological and molecular diagnosis of gliomas. This classification allows for the diagnosis of isocitrate dehydrogenase wild-type (IDHwt) glioblastoma (GBM), and WHO grade 4 with histologically lower-grade gliomas (LrGGs), even in the absence of high-grade histopathologic features, such as necrosis and/or microvascular proliferation. They contain at least one of the following molecular features: epidermal growth factor receptor amplification, chromosome 7 gain/10 loss, or telomerase reverse transcriptase promoter mutation...
March 29, 2023: Brain Tumor Pathology
https://read.qxmd.com/read/36892668/clinical-histopathological-and-molecular-risk-factors-for-recurrence-of-pilocytic-astrocytomas-brainstem-spinal-location-nestin-expression-and-gain-of-7q-and-19-are-associated-with-early-tumor-recurrence
#35
JOURNAL ARTICLE
Ryota Tamura, Akio Iwanami, Kentaro Ohara, Masaaki Nishimoto, Eriel Sandika Pareira, Tomoru Miwa, Naoko Tsuzaki, Yuki Kuranari, Yukina Morimoto, Masahiro Toda, Hideyuki Okano, Masaya Nakamura, Kazunari Yoshida, Hikaru Sasaki
Pilocytic astrocytomas (PAs) are benign tumors. However, clinically aggressive PAs despite benign histology have been reported, and histological and molecular risk factors for prognosis have not been elucidated. 38 PAs were studied for clinical, histological, and molecular factors, including tumor location, extent of resection, post-operative treatment, glioma-associated molecules (IDH1/2, ATRX, BRAF, FGFR1, PIK3CA, H3F3A, p53, VEGF, Nestin, PD-1/PD-L1), CDKN2A/B deletion, and chromosomal number aberrations, to see if there is any correlation with patient's progression-free survival (PFS)...
March 9, 2023: Brain Tumor Pathology
https://read.qxmd.com/read/36811792/high-grade-neuroepithelial-tumor-with-ep300-bcor-fusion-and-negative-bcor-immunohistochemical-expression-a-case-report
#36
JOURNAL ARTICLE
Hirokazu Sugino, Kaishi Satomi, Taisuke Mori, Yuuki Mukai, Mai Honda-Kitahara, Yuko Matsushita, Koichi Ichimura, Yoshitaka Narita, Akihiko Yoshida
In the World Health Organization tumor classification (fifth edition), central nervous system (CNS) tumors with BCOR internal tandem duplications have been recognized as a new tumor type. Some recent studies have reported CNS tumors with EP300::BCOR fusions, predominantly in children and young adults, expanding the spectrum of BCOR-altered CNS tumors. This study reports a new case of high-grade neuroepithelial tumor (HGNET) with an EP300::BCOR fusion in the occipital lobe of a 32-year-old female. The tumor displayed anaplastic ependymoma-like morphologies characterized by a relatively well-circumscribed solid growth with perivascular pseudorosettes and branching capillaries...
February 22, 2023: Brain Tumor Pathology
https://read.qxmd.com/read/36550382/correlation-of-mtap-immunohistochemical-deficiency-with-cdkn2a-homozygous-deletion-and-clinicopathological-features-in-pleomorphic-xanthoastrocytoma
#37
JOURNAL ARTICLE
Lei Lou, Jiajun Li, Manman Qin, Xiaoxi Tian, Wenli Guo, Yuehong Li
Pleomorphic xanthoastrocytoma (PXA) is a rare tumor ranging from World Health Organization (WHO) grades 2-3 and can potentially recur and metastasize throughout the central nervous system (CNS). Cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) deletion is a frequent genomic alteration of PXA. Methylthioadenosine phosphorylase (MTAP) immunohistochemistry is a promising surrogate marker for CDKN2A homozygous deletion in different cancers but has not been examined in PXA. Therefore, we performed CDKN2A fluorescence in situ hybridization and MTAP immunohistochemistry on specimens from 23 patients with CNS WHO grades 2 (n = 10) and 3 (n = 13) PXAs, including specimens from primary and recurrent tumors, and determined whether MTAP immunohistochemistry correlated with CDKN2A homozygous deletion and clinicopathological features...
January 2023: Brain Tumor Pathology
https://read.qxmd.com/read/36538117/update-of-the-2021-who-classification-of-tumors-of-the-central-nervous-system-adult-diffuse-gliomas
#38
EDITORIAL
Takashi Komori
No abstract text is available yet for this article.
January 2023: Brain Tumor Pathology
https://read.qxmd.com/read/36370248/three-dimensional-visualization-of-human-brain-tumors-using-the-cubic-technique
#39
JOURNAL ARTICLE
Yangyang Xu, Qi He, Mengqi Wang, Yang Wu, Yifeng Shi, Wei Wang, Jie Zhang
Application of tissue clearing techniques on human brain tumors is still limited. This study was to investigate the application of CUBIC on 3D pathological studies of human brain tumors. Brain tumor specimens derived from 21 patients were cleared with CUBIC. Immunostaining was conducted on cleared specimens to label astrocytes, microglia and microvessels, respectively. All tumor specimens achieved transparency after clearing. Immunostaining and CUBIC are well compatible in a variety of human brain tumors. Spatial morphologies of microvessels, astrocytes and microglia of tumors were clearly visualized in 3D, and their 3D morphological parameters were easily quantified...
January 2023: Brain Tumor Pathology
https://read.qxmd.com/read/36107277/an-extracranial-cns-presentation-of-the-emerging-intracranial-mesenchymal-tumor-fet-creb-fusion-positive
#40
JOURNAL ARTICLE
Arnault Tauziède-Espariat, Gaëlle Pierron, Delphine Guillemot, Chiara Benevello, Johan Pallud, Joseph Benzakoun, Lauren Hasty, Alice Métais, Fabrice Chrétien, Pascale Varlet
A novel histomolecular tumor, the "intracranial mesenchymal tumor (IMT), FET::CREB fusion-positive", has recently been identified and added to the 2021 World Health Organization Classification of Tumors of the Central Nervous System. One of the essential diagnostic criteria defined in this classification is the intracranial location of the tumor. Herein, we report a spinal case of IMT with a classical EWSR1::CREM fusion. We compare its clinical, histopathological, immunophenotypical, genetic and epigenetic features with those previously described in IMT, FET::CREB fusion-positive...
January 2023: Brain Tumor Pathology
journal
journal
32882
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.